• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2021 o Market outlook: Forecast for 2021 - 2026 • Five Forces Analysis o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Deployment o Market segments o Comparison by Deployment o Captive APIs - Market size and forecast 2021-2026 o Contract APIs - Market size and forecast 2021-2026 o Market opportunity by Deployment • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2021-2026 o Asia - Market size and forecast 2021-2026 o Europe - Market size and forecast 2021-2026 o ROW - Market size and forecast 2021-2026 o Key leading countries o Market opportunity By Geographical Landscape o Market drivers o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Aurobindo Pharma Ltd. o Cambrex Corp. o Cipla Inc. o Dr. Reddys Laboratories Ltd. o GlaxoSmithKline Plc o Merck KGaA o Novartis AG o Pfizer Inc. o Teva Pharmaceutical Industries Ltd. o Viatris Inc. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibits • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2021 - 2026 ($ billion) • 13: Global market: Year-over-year growth 2021 - 2026 (%) • 14: Five forces analysis 2021 & 2026 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2021 • 21: Deployment - Market share 2021-2026 (%) • 22: Comparison by Deployment • 23: Captive APIs - Market size and forecast 2021-2026 ($ billion) • 24: Captive APIs - Year-over-year growth 2021-2026 (%) • 25: Contract APIs - Market size and forecast 2021-2026 ($ billion) • 26: Contract APIs - Year-over-year growth 2021-2026 (%) • 27: Market opportunity by Deployment • 28: Customer landscape • 29: Market share By Geographical Landscape 2021-2026 (%) • 30: Geographic comparison • 31: North America - Market size and forecast 2021-2026 ($ billion) • 32: North America - Year-over-year growth 2021-2026 (%) • 33: Asia - Market size and forecast 2021-2026 ($ billion) • 34: Asia - Year-over-year growth 2021-2026 (%) • 35: Europe - Market size and forecast 2021-2026 ($ billion) • 36: Europe - Year-over-year growth 2021-2026 (%) • 37: ROW - Market size and forecast 2021-2026 ($ billion) • 38: ROW - Year-over-year growth 2021-2026 (%) • 39: Key leading countries • 40: Market opportunity By Geographical Landscape ($ billion) • 41: Impact of drivers and challenges • 42: Vendor landscape • 43: Landscape disruption • 44: Industry risks • 45: Vendors covered • 46: Market positioning of vendors • 47: Aurobindo Pharma Ltd. - Overview • 48: Aurobindo Pharma Ltd. - Product and service • 49: Aurobindo Pharma Ltd. - Key offerings • 50: Aurobindo Pharma Ltd. - Key customers • 51: Aurobindo Pharma Ltd. - Segment focus • 52: Cambrex Corp. - Overview • 53: Cambrex Corp. - Product and service • 54: Cambrex Corp. - Key offerings • 55: Cambrex Corp. - Key customers • 56: Cambrex Corp. - Segment focus • 57: Cipla Inc. - Overview • 58: Cipla Inc. - Business segments • 59: Cipla Inc. - Key offerings • 60: Cipla Inc. - Key customers • 61: Cipla Inc. - Segment focus • 62: Dr. Reddys Laboratories Ltd. - Overview • 63: Dr. Reddys Laboratories Ltd. - Business segments • 64: Dr. Reddys Laboratories Ltd. - Key offerings • 65: Dr. Reddys Laboratories Ltd. - Key customers • 66: Dr. Reddys Laboratories Ltd. - Segment focus • 67: GlaxoSmithKline Plc - Overview • 68: GlaxoSmithKline Plc - Business segments • 69: GlaxoSmithKline Plc - Key offerings • 70: GlaxoSmithKline Plc - Key customers • 71: GlaxoSmithKline Plc - Segment focus • 72: Merck KGaA - Overview • 73: Merck KGaA - Business segments • 74: Merck KGaA - Key offerings • 75: Merck KGaA - Key customers • 76: Merck KGaA - Segment focus • 77: Novartis AG - Overview • 78: Novartis AG - Business segments • 79: Novartis AG - Key offerings • 80: Novartis AG - Key customers • 81: Novartis AG - Segment focus • 82: Pfizer Inc. - Overview • 83: Pfizer Inc. - Business segments • 84: Pfizer Inc. - Key offerings • 85: Pfizer Inc. - Key customers • 86: Pfizer Inc. - Segment focus • 87: Teva Pharmaceutical Industries Ltd. - Overview • 88: Teva Pharmaceutical Industries Ltd. - Business segments • 89: Teva Pharmaceutical Industries Ltd. - Key offerings • 90: Teva Pharmaceutical Industries Ltd. - Key customers • 91: Teva Pharmaceutical Industries Ltd. - Segment focus • 92: Viatris Inc. - Overview • 93: Viatris Inc. - Business segments • 94: Viatris Inc. - Key offerings • 95: Viatris Inc. - Key customers • 96: Viatris Inc. - Segment focus • 97: Currency conversion rates for US$ • 98: Research Methodology • 99: Validation techniques employed for market sizing • 100: Information sources • 101: List of abbreviations

Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc.